UroGen Pharma Ltd. (URGN)

NGM – Цена в реальном времени. Валюта: USD

29.80

-1.53 (-4.88%)

При закрытии: May 12, 2026, 4:00 PM EDT

30.07

+0.27 (0.91%)

После закрытия: May 12, 2026, 7:12 PM EDT

11.05.2026

Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?

From a technical perspective, Urogen Pharma (URGN) is looking like an interesting pick, as it just reached a key level of support. URGN's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

07.05.2026

UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027

UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, reflecting robust Q1 2026 results. Zusduri sales more than doubled QoQ to $29.2M, driven by the January J-code assignment, validating the trajectory toward profitability by 2027. URGN's path to profitability is underpinned by >91% gross margins, disciplined expense control, and a realistic break-even threshold of $305M annual revenue.

07.05.2026

UroGen Pharma to Present at Upcoming Investor Conferences

PRINCETON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

06.05.2026

UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript

06.05.2026

Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates

Urogen Pharma (URGN) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.92 per share a year ago.

06.05.2026

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

ZUSDURI™ generated revenue of $29.2 million in Q1 2026, representing 109% quarter-over-quarter growth, reflecting broader utilization with the permanent J Code effective January 1, 2026 JELMYTO achieved $21.7 million in revenue in Q1 2026, representing year-over-year growth of 7% Continued advancement of next-generation pipeline, UGN-103 on track for NDA submission in the second half of 2026; six-month durability data expected in mid-2026 UroGen to host Key Opinion Leader (KOL) panel highlighting real-world experience with ZUSDURI at the American Urological Association (AUA) annual meeting on May 17 th at 8:30 AM ET Conference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

29.04.2026

UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET

UroGen Pharma Ltd. (URGN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

UroGen Pharma Ltd. (URGN)

Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?

UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript

Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?

UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript

Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

Видео

No Data

Пресс-релизы

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

UroGen Pharma Ltd. (URGN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

UroGen Pharma Ltd. (URGN)

Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?

UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript

Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?

UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call Transcript

Urogen Pharma (URGN) Reports Q1 Loss, Beats Revenue Estimates

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

Видео

No Data

Пресс-релизы

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)